These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18544732)

  • 1. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.
    Hede K
    J Natl Cancer Inst; 2008 Jun; 100(12):836-7, 844. PubMed ID: 18544732
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinctive biology of pleomorphic lobular carcinoma of the breast.
    Moe RE; Anderson BO
    J Surg Oncol; 2005 May; 90(2):47-50. PubMed ID: 15844193
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
    Hammond ME; Hayes DF; Wolff AC
    J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
    [No Abstract]   [Full Text] [Related]  

  • 5. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.
    Allred DC
    Oncologist; 2008 Nov; 13(11):1134-6. PubMed ID: 18987048
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular subtyping of early-stage breast cancer: implications for radiation therapy.
    Haffty BG; Goyal S
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1293-5. PubMed ID: 20637976
    [No Abstract]   [Full Text] [Related]  

  • 11. Axillary tumour.
    Martins A; Serrão V; Fiadeiro T; Lopes MP; Campos F; Pereira H; Rodrigues JC
    Histopathology; 2008 Apr; 52(5):654-5. PubMed ID: 18312349
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen receptor testing of breast cancer in current clinical practice: what's the question?
    Schnitt SJ
    J Clin Oncol; 2006 Apr; 24(12):1797-9. PubMed ID: 16567766
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
    Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
    Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue microarray for routine clinical breast biomarker analysis. The British Columbia Cancer Agency 2008 experience.
    Thomson TA; Zhou C; Ceballos K; Knight B
    Am J Clin Pathol; 2010 Jun; 133(6):909-14. PubMed ID: 20472849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of histopathological markers for response to primary systemic therapy].
    Sato N
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():409-13. PubMed ID: 23350432
    [No Abstract]   [Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 17. Alternate-site testing. Consider the analyst.
    Allred TJ; Steiner L
    Clin Lab Med; 1994 Sep; 14(3):569-604. PubMed ID: 7805347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality assurance in HER2 testing].
    Sakatani T; Ohzawa H
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():418-22. PubMed ID: 23350434
    [No Abstract]   [Full Text] [Related]  

  • 19. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute risk models for subtypes of breast cancer.
    Gail MH; Anderson WF; Garcia-Closas M; Sherman ME
    J Natl Cancer Inst; 2007 Nov; 99(22):1657-9. PubMed ID: 18000214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.